Revvity outlines ~6% organic growth view for 2027
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Revvity, Inc. (RVTY) used its November 13, 2026 Investor Day to outline its strategy and financial outlook. Management estimated 2026 revenue at ~$2.9 billion, adjusted EPS at ~$5.43, adjusted operating margin at ~28.8%, and free cash flow above $575 million, with FCF conversion above 90%. These 2026 estimates and historical growth rates are based on 2026 pro forma guidance provided November 3, 2026, and exclude the Immunodiagnostics business in China, which is under a definitive agreement to be divested.
The long-range plan includes 75 bps of operating-margin expansion and double-digit adjusted EPS growth. Management’s 2027 considerations include ~6% organic growth, ~200 bps above market growth, and ~20 bps in addition to normal operating leverage; formal 2027 guidance will be provided on the Q4 earnings call. From 2023 to 2026, headcount was reduced ~16% and global square footage ~25%. Revvity described its portfolio as connecting biology, experimental data, and software to support AI-enabled discovery.
Filing Explained
The listed buybacks, M&A and dividend policy are future intentions, not completed capital deployments.
The 8-K furnishes Revvity’s
For
The roughly
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
2026E revenue: ~$2.9 billion
2026E adjusted EPS: ~$5.43 per share
2026E adjusted operating margin: ~28.8%
+5 more
8 metrics
2026E revenue
~$2.9 billion
2026 estimate
2026E adjusted EPS
~$5.43 per share
2026 estimate
2026E adjusted operating margin
~28.8%
2026 estimate
2026E free cash flow
> $575 million
2026 estimate
Immunodiagnostics long-range organic growth
7-9%
Long-range plan
Reproductive Health long-range organic growth
3-5%
Long-range plan
Life Sciences Solutions long-range organic growth
6-8%
Long-range plan
Signals Software long-range APV growth
10-12%
Long-range plan; based on annualized portfolio value
Key Terms
Annual recurring revenue, Annualized portfolio value, Net retention rate, non-GAAP financial measures, +1 more
5 terms
Annual recurring revenue financial
"ARR = Annual recurring revenue"
Annual recurring revenue is the predictable amount of money a company expects to earn each year from ongoing customer subscriptions or contracts. It helps businesses understand how much steady income they can count on, much like a subscription service that charges customers every month or year. This figure is important because it shows the company's stability and growth potential.
Annualized portfolio value financial
"APV = Annualized portfolio value"
Net retention rate financial
"Net retention rate Average renewal upsell minus average renewal churn"
Net retention rate measures how much revenue a company keeps and grows from its existing customers over a set period, after accounting for expansions, contractions and lost customers. Think of it like checking whether a garden of existing plants is producing more fruit this year than last — it shows whether the current customer base is becoming more valuable or shrinking. Investors use it to judge revenue sustainability and growth potential without relying on new customers.
non-GAAP financial measures financial
"this presentation also includes non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Long-range plan financial
"LRP = Long-range plan"
A long-range plan is a multi-year roadmap a company lays out to show its major goals, the steps and investments needed to reach them, and the assumptions behind those choices. Investors use it like a map to judge whether management has a realistic path to growth or profit, to anticipate future capital needs, and to weigh the likely risks and rewards of holding or buying the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Revvity (RVTY) estimate for 2026?
Revvity estimated 2026 revenue of ~$2.9 billion, adjusted EPS of ~$5.43, adjusted operating margin of ~28.8%, and free cash flow above $575 million. The estimates are based on 2026 pro forma guidance provided November 3, 2026, and exclude the Immunodiagnostics business in China, which is under a definitive agreement to be divested.
What are Revvity's (RVTY) long-range growth targets by business?
The long-range plan sets organic-growth targets of 7-9% for Immunodiagnostics, 3-5% for Reproductive Health, and 6-8% for Life Sciences Solutions. Signals Software's target is 10-12% based on annualized portfolio value (APV).
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 13, 2026
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: (781 ) 663-6900
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||||||||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure
On November 13, 2026 , Dr. Prahlad Singh, President and Chief Executive Officer of Revvity, Inc. (the “Company”), along with other members of the Company’s senior management team will provide updates on the Company’s key business initiatives, operational achievements and financial outlook at the Company’s Investor Day 2026, beginning at 9:00am ET. The full text of the press release and the presentation issued in connection with Investor Day 2026 are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
EXHIBIT INDEX
| Exhibit No. | Description | |||||||||||||
| 99.1* | Press Release entitled “Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day”, issued by Revvity, Inc. on November 13, 2026 | |||||||||||||
| 99.2* | Investor Day 2026 Presentation, November 13, 2026 | |||||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL) | |||||||||||||
* The exhibits relating to Item 7.01 shall be deemed to be furnished, and not filed.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| REVVITY, INC. | |||||
Date: November 13, 2026 | By: /s/ Maxwell Krakowiak Maxwell Krakowiak Senior Vice President and Chief Financial Officer | ||||
November 13, 2026
Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day
•The 2026 Investor Day on November 13 at 9:00 a.m. EST will demonstrate how Revvity is “Powering Scientific Intelligence”
•Revvity connects biology, experimental data and scientific insights to support AI-enabled discovery workflows through specialized research, diagnostics and software capabilities
•Company to provide its latest views on long-term outlook, demonstrating a strong position to deliver above-market growth and sustained shareholder value
WALTHAM, Mass. -- Revvity, Inc. (NYSE: RVTY) today will host its 2026 Investor Day, highlighting the Company's differentiated portfolio of Life Sciences and Diagnostics solutions, as well as its position at the intersection of biology, experimentation and data.
Under the theme "Powering Scientific Intelligence," Prahlad Singh, president and chief executive officer, and members of Revvity's senior leadership team will outline the Company's strategic priorities, recent operational initiatives, and long-range financial outlook.
"Since becoming Revvity in 2023, we have made significant progress building a more focused, innovative, and connected company," said Singh. "Our differentiated portfolio and unique capabilities position us well to support the next era of scientific discovery. Combined with our continued focus on operational excellence, we are confident in our ability to deliver sustained, above-market growth and long-term shareholder value. "
During the event, Revvity will highlight three key areas:
•A differentiated portfolio: Strong positions across attractive Life Sciences and Diagnostics markets, supported by innovative research solutions, specialized diagnostic technologies and leading software capabilities.
•Positioned for the future of scientific discovery: Unique capabilities that connect biology, experimental data, and scientific insights to support increasingly AI-enabled discovery workflows and the growing demand for high-quality experimental evidence.
•Compelling long-term value creation: Continued execution of efforts to simplify the organization, optimizing operational performance, and advancing strategic priorities to support above-market growth and margin expansion.
Webcast
To register for the Investor Day webcast, please visit here. A replay of the webcast will also be available on the website following the event. The accompanying presentation can be found on the Events and Presentations section of the Revvity Investor Relations website.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook, and Instagram.
Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com
Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com
©2026 Revvity, Inc.©2026 Revvity, Inc. All rights reserved. Powering scientific intelligence Transforming insight into impact INVESTOR DAY 2026 | November 13
Welcome and Opening Remarks Steve Willoughby Senior VP, Investor Relations, ESG, Risk ©2026 Revvity, Inc.
©2026 Revvity, Inc. Safe Harbor 3 This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, and acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations, and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward- looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also includes non-GAAP financial measures. Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items we exclude from these non-GAAP measures. The amounts and timing of such events and items could be material to our results prepared in accordance with GAAP.
©2026 Revvity, Inc. 4 Financial Disclosures Estimated future results and historical growth rates presented and discussed today are based on 2026 pro forma guidance as provided on November 3, 2026 (2026E) and exclude: • Immunodiagnostics business in China which is currently under a definitive agreement to be divested Key Definitions: • LSD = 1-3% • MSD = 4-6% • HSD = 7-9% • LDD = 10-12% • LRP = Long-range plan • ARR = Annual recurring revenue • APV = Annualized portfolio value
©2026 Revvity, Inc. i , I . Agenda Steve Willoughby | Senior VP, Investor Relations, ESG, RiskWelcome1 Prahlad Singh, PhD | President and CEO Company Overview2 Kevin Willoe | President, Signals SoftwareSignals Software Overview3 Craig Monell, PhD | Senior VP, Reagents David Gosalvez, PhD | Chief Strategy Officer, Signals Software New Era of Scientific Discovery4 Driving Operational Success and Creating Long-Term Value Max Krakowiak | Senior VP, CFO5 5
Powering scientific intelligence Prahlad Singh, PhD President and CEO ©2026 Revvity, Inc.
©2026 Revvity, Inc. Expanding the boundaries of human potential through science Our purpose 7 Revolutionizing science and transforming human lives through groundbreaking innovation
©2026 Revvity, Inc. 8 i , I . Strong positions in specialty clinical areas Unique reagents, instruments and software capabilities Driving faster and deeper experimentation and learning We are an innovative and differentiated Life Sciences and Diagnostics company Bringing together scientific data, context and decisions Differentiated, connected offerings spanning Life Sciences and Diagnostics Diagnostics delivering durable growth Life Sciences providing scientific answers Connecting critical workflows Positioned for the future of drug discovery Advancing science and improving health 8
©2026 Revvity, Inc. Revvity at-a-glance 9 2026E Revenue: ~$2.9B Segments Geography ~45% Americas ~20% APAC ~35% EMEA ~85% Recurring Revenue* ~15% Non-recurring Revenue ~55% Life Sciences ~45% Diagnostics Powered by ~10,000 employees collaborating to pioneer groundbreaking solutions *Consumables, services and software Products
©2026 Revvity, Inc. Diagnostics at-a-glance 10 $30B+ Addressable market MSD 5-year market CAGR Broad portfolio in specialty areas spanning newborn, autoimmune and infectious disease screening ~55% Immunodiagnostics ~45% Reproductive Health Segment Revenue (2026E) ~$1.4B ~90% Recurring Revenue Strong innovation engine and global presence Automated workflow solutions to meet unique customer needs Offering complete screening solutions that enable earlier diagnosis, intervention and more informed treatment guidance
©2026 Revvity, Inc. Immunodiagnostics at-a-glance 11 Autoimmune A global leader with broad testing menu Infectious disease Continuing to improve positioning in this high-growth market Specialized, high-growth Immunodiagnostics business Strong positions in: ~60% Autoimmune ~35% Infectious disease ~5% Allergy & other Revenue (2026E) ~$0.8B
©2026 Revvity, Inc. Highlighting our Immunodiagnostics portfolio 12 Acute and chronic infectious disease diagnostics across a range of automated throughput needs A comprehensive menu of highly sensitive tests, innovative automation and AI- supported software for non-routine, specialized autoimmune diagnostics Autoimmune assays Infectious disease assays Automated nucleic acid extraction Autoimmune Infectious disease Automated analyzers Examples: rheumatoid arthritis, multiple sclerosis, lupus and 80+ rare conditions Select offerings: Comprehensive allergy testing solutions supported by automation solutions and specialized diagnostic expertise Automation systems Allergy & other Allergy assays
©2026 Revvity, Inc. Reproductive Health at-a-glance 13 40+ years of newborn screening leadership Deep integration across workflows and strong commercial execution support sustainable above-market growth Established global footprint and strong presence in public health NBS programs Revenue (2026E) ~$0.6B85+ newborn lives saved daily in Newborn Screening#1 ~10% Maternal and prenatal health ~10% Cord blood banking ~10% Multiomics services ~70% Newborn screening
©2026 Revvity, Inc. Highlighting our Reproductive Health portfolio 14 Newborn screening Maternal & prenatal health Cord blood banking Multiomics services Offers complete workflow solutions from sample to result. Over 760M infants screened using our advanced technologies Delivers newborn cord blood and tissue banking services, from collection through long-term storage Provides full workflow offerings for all trimesters, including products for NIPT and pre-eclampsia Leverages multiomics-based technologies to provide insights into diagnosis, monitoring and treatment NBS immunoassay system Cord blood banking kits Whole genome sequencing Placental growth factor (PIGF) testing Select offerings:
©2026 Revvity, Inc. 15 Our unique positions in specialty diagnostics provide a strong foundation to expand access to more actionable clinical answers
©2026 Revvity, Inc. Building a nephrology portfolio with high-value testing and next-generation biomarkers 16 9 in 10 adults who have chronic kidney disease are undiagnosed Expanding our autoimmune portfolio to provide patients with diagnostic answers and help monitor response Driving innovation through multiple testing technologies ELISA | IIFT | ChLIA | Immunoblot An IVD portfolio that… Identifying biomarkers that… Identifies the autoantibodies behind immune-related disease Assists treatment response Assesses kidney function Explore immune-related damage to kidney filters Study inflammation in kidney disease Innovation Spotlight Source for U.S. kidney disease diagnoses: CDC
©2026 Revvity, Inc. Shaping the future of newborn screening 17 We offer comprehensive workflows and are a global market leader in dried blood spot testing Continuing to advance newborn screening through complementary approaches Sample collection Extraction and QC Library prep and QC Sequencing services Analysis software LI M S an d da ta a na ly si s in te gr at io n ac ro ss w or kf lo w 1 2 3 4 5 ✓ Configurable to a customer’s laboratory ✓ Access to our highly curated proprietary genomic database ✓ Integration with existing NBS software ✓ Global lab network ready to support our customers Looking ahead: One complete NGS workflow for newborn screening labs, enabling an integrated screening solution Innovation Spotlight
©2026 Revvity, Inc. Building on our newborn leadership to expand into population screening 18 Developing a multiplex assay from one dried blood spot Leveraging screening relationships and dried blood spot expertise BioLegend: High-quality, validated reagents Reproductive Health: Commercial scalability and assay development Global lab footprint: Screening services Type 1 Diabetes Autoimmune thyroid disease Celiac disease Our integrated capabilities Future applications Euroimmun: Automation and disease area expertise Innovation Spotlight
©2026 Revvity, Inc. Bringing together differentiated capabilities to advance precision medicine 19 Life Sciences DiagnosticsBridging the gap from discovery to cure Applying our portfolio to diverse applications + OncologyRare disease Chronic disease Supporting an innovative customer base
©2026 Revvity, Inc. Life Sciences at-a-glance 20 $30B+ Addressable market MSD 5-year market CAGR Portfolio spanning automation, imaging, detection, cellular analysis, reagents and software ~85% Recurring Revenue Consistent track record of innovation and novel IP Integrated solutions help customers generate richer data, accelerate decisions and improve research outcomes ~15% Signals Software ~85% Life Sciences Solutions (LSS) ~$1.5B Segment Revenue (2026E) Driving differentiation through an integrated portfolio of Reagents & Instruments (LSS) and Signals Software that power scientific discovery
©2026 Revvity, Inc. Signals Software at-a-glance Leading provider of scientific SaaS Empowering scientists and decision- makers to gain critical insights from data analytics, accelerating informed decisions ~$260M 2026E Revenue 1M+ users across 4,000+ customers worldwide #1 ELN (Electronic Lab Notebook) provider Broad adoption in pharma research with expansion opportunities in development & manufacturing 21 From in-silico to the wet lab… …and from small molecule to novel therapies 46/50 top pharma and biotech companies
©2026 Revvity, Inc. Reagents at-a-glance Offers assays that help customers gain deeper insights into cellular biology Dedicated global Centers of Excellence, supporting reliable supply and faster delivery to customers Unique biomarker development and detection capabilities ~$0.7B Revenue (2026E) ~55% RUO antibodies ~45% Research reagents 75k+ reagents offered 22 Reagents supporting research from early discovery through drug development
©2026 Revvity, Inc. Highlighting our Reagents portfolio 23 Differentiated biological content, assay technologies and scientific expertise support critical workflows RUO antibodies Research reagents Features reagents and consumables, including antibodies for flow cytometry, recombinant proteins and multiomics assay kits Antibody conjugates Alpha assays Offers reagents for cell function and viability, as well as immunoassay kits that provide an alternative to traditional ELISA Select offerings:
©2026 Revvity, Inc. Instruments at-a-glance Providing expertise, technology and capabilities from basic research through drug development High-value instruments with complementary reagents and software Automating complex cellular analysis to accelerate research Global instrument Centers of Excellence provide specialized expertise to accelerate innovation ~20% Detection ~30% Cellular analysis ~30% Sample prep & automation ~20% In vivo imaging ~$0.5B Revenue (2026E) 24
©2026 Revvity, Inc. Highlighting our Instruments portfolio 25 Offers cell counters and high-content screening platforms that provide a fast and accurate way to assess cells Advanced preclinical imaging solutions (i.e. optical, microCT, ultrasound) with user-friendly software that leverages AI integration Multimode plate readers and radiometric detection tools to support functional insights IVIS SpectrumTM 2 EnVision NexusTM Opera Phenix OptIQTM Cellular analysis In vivo imaging Detection Select offerings: Automated sample preparation platforms across liquid handling and robotics FontusTM Sample prep & automation Plate reader Optical imaging Liquid handling High-content screening
©2026 Revvity, Inc. 26 Advancing the next generation of Life Sciences innovation with our unique reagents, instruments and software solutions
©2026 Revvity, Inc. Continuous innovation driving sustained growth 27 Expanding scientists' ability to generate high-quality biological data and accelerate discovery 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Revenue contribution from new LSS reagents by year ~1,500 new reagents, kits and antibodies developed annually Innovation Spotlight
©2026 Revvity, Inc. Innovative software drives additional value across our Life Sciences portfolio 28 Integrating novel software from across Revvity into the Signals platform, helping researchers answer critical questions while creating differentiated competitive advantages • AI-based, in vivo image segmentation and faster data quantification • Combines optical imaging, microCT and ultrasound data Living ImageTM Synergy AI • Cloud-based flow cytometry data management and analysis • Supports panel design and interpretation CytoScribeTM Multi-modal data: Innovation Spotlight • Cloud-based, AI-powered HCS and cell imaging analysis • Accelerates image processing to turn data into insights Image ArtistTM
©2026 Revvity, Inc. 29 Uniquely positioned in specialized, high-growth markets, serving a diverse customer base Key customers Life Sciences Diagnostics Pharma / Biotech Academia / Government Reference Labs Hospitals / Clinics Public Health Labs ~$1.5B ~85% Life Sciences Solutions ~15% Signals Software ~$1.4B ~55% Immuno- diagnostics ~45% Reproductive Health Segment breakdown 2026E Revenue 2026 evvity, Inc.
©2026 Revvity, Inc. What you will hear today 30 Set to deliver compelling long-term value creation Continued confidence in the long-range outlook Revvity is: Positioned for the future of scientific discovery Unique capabilities across biology, measurement and data integration A differentiated portfolio Strong positions across attractive Diagnostics and Life Sciences markets
Kevin Willoe President, Signals Software Revvity Signals Connecting the scientific workflow ©2026 Revvity, Inc.
©2026 Revvity, Inc. Key Messages 32 EMBEDDED IN HOW SCIENCE IS DONE Digital system of record connecting scientific workflows from idea to creation MORE VALUABLE AS SCIENCE TRANSFORMS Unified platform enabling customers to realize greater value from accelerated data generation and AI-enabled workflows PROVEN FOUNDATION FOR GROWTH Scaled platform with a robust innovation engine driving sustainable long-term growth Connecting scientific work & turning data into decisions SIGNALS SOFTWARE
©2026 Revvity, Inc. What is Revvity Signals ? 33 Scientific software that enables teams to plan and carry out research, understand their data and decide what comes next What are we trying to create? How do we carry out the work? What are the results telling us? What should we do next? Develop ideas, explore predictions and plan experiments Coordinate experiments and samples and record the work and results Analyze results, identify patterns and understand performance Prioritize promising ideas and determine the next steps DESIGN MAKE DECIDE Supporting scientific workflows while creating a trusted foundation of data and experimental records for downstream development TEST TM
©2026 Revvity, Inc. As technology has evolved… 2015 - 20202000 - 20151985 - 2000 The Birth of Cheminformatics Cheminformatics for the Enterprise Re-platforming for SaaS 2025 and beyond2020 - 2025 SaaS Platform Expansion Operationalizing Scientific AI Personal Computers The Internet SaaS AI ChemDraw ChemBioOffice E-Notebook Enterprise ChemOffice Enterprise Spotfire Signals Notebook Signals Lead Discovery Signals VitroVivo Signals ChemDraw Signals One Signals Clinical Signals BioDesignSignals Synergy Signals Xynthetica AI Co-Scientist Signals LabGistics …Signals has evolved with it The Cloud 34
©2026 Revvity, Inc. Signals’ operating metrics reflect the recurring, expanding nature of the business… Key software metrics 2020 2026E >$100M ARR Annual recurring revenue Total expected revenue over the next 12 months from SaaS contracts 13% CAGR >$275M >$130M APV Annualized portfolio value Annual value of contracts assuming linear revenue recognition …driven by customer retention, platform expansion and contracted portfolio growth ~5% SaaS penetration % of annual revenue from cloud- based solutions (vs desktop) ~35% 40% CAGR Net retention rate Average renewal upsell minus average renewal churn~$10M 47% CAGR ~107% historical average Evolving beyond the traditional user-based model Pay-per-use pricing Self-funding growth Customers pay for what they consume, not just user seats AI investments generate direct revenue as customers consume more services Storage-based pricing As AI advancements drive increased data generation, customers pay to store it 35
©2026 Revvity, Inc. it , I . 36 Why customers choose Revvity Signals Software • Transformational capabilities • Enterprise-grade security • Scientific system of record • Depth & breadth • SaaS done right • Proven at scale 2026 evv y nc
©2026 Revvity, Inc. Turning scattered scientific activity into a system of record 37 FRAGMENTED SYSTEMS CONNECTED KNOWLEDGE Experiments & protocols Analytics & AI Samples, results & conditions Institutional memory Teams & workflows Samples, results & conditions Experiments & protocols Teams & workflows Institutional memory Analytics & AI A scientific system of record preserving the context behind every decision Context lost between tools teams repeat work Context kept with the data teams reuse it
©2026 Revvity, Inc. Serving scientists across disciplines and the R&D lifecycle 38 Large Molecule Research Small Molecule Research Formulations Research Testing Assay Development Large Molecule Development Small Molecule Development Formulations Development CMC QA/QC Clinical Trials Analytics AI-Augmented Design Research Development Pre-Clinical + Manufacturing A single, unified platform helps customers keep scientific work, data and decisions connected across the R&D lifecycle
©2026 Revvity, Inc. A comprehensive, unified software platform of modularized, transformative solutions 39 Innovative chemical drawing standard for small molecules and biopolymers Advanced scientific analytics and visualization platform Revvity Signals Technology Framework - SaaS done right Novel CRO integration for seamless data capture and collaboration Just-in-time clinical trial data analytics Intuitive data capture and collaboration with self- service integration End-to-end support across multiple scientific disciplines Digitalize and unify complex scientific workflows to accelerate them Cloud-native planning, visualizing and simulating large molecule designKey Module:
©2026 Revvity, Inc. Delivering unprecedented depth and breadth… 40 Large Molecule Research Small Molecule Research Formulations Research Testing Assay Development Large Molecule Development Small Molecule Development Formulations Development CMC QA/QC Clinical Trials Analytics AI-Augmented Design Research Development Pre-Clinical + Manufacturing Offering new solutions to extend our presence into additional disciplines, user groups and stages of R&D Breadth With growing opportunity to fold in high-value software assets from broader Revvity Expanding existing capabilities to increase penetration in our scientific communities and workflows Depth …and expanding reach across Tiers 2 & 3 Biopharma and Materials Science customers
©2026 Revvity, Inc. Streamlining scientific workflows across the R&D lifecycle with LabGistics 41 Capturing the complexity of scientific work to accelerate it Innovation spotlight: Accelerate technology transfer through seamless handoffs between development and manufacturing processes Simplify regulatory compliance by supporting documentation and traceability in GxP environments Capture complex workflows using AI tools that convert SOPs and natural language descriptions into repeatable processes Single source of truth for scientific operations TM
©2026 Revvity, Inc. Helping scientists answer complex biological questions faster 42 A scalable Models- as-a-Service offering that converges with the wet lab Partnership spotlight: Building on Signals One to enable a continuous learning system Transformational Federated Learning platform Innovation spotlight: ✓ Flexible AI model ecosystem supporting proprietary, third- party and Revvity-developed models ✓ Seamless integration of in-silico and wet-lab workflows to accelerate scientific discovery ✓ Secure federated learning that connects insights while protecting proprietary data
©2026 Revvity, Inc. The AI-driven transformation of science further expands Signals’ opportunity Signals has evolved into a broad, connected scientific platform The platform is embedded in customer workflows and serves as a scientific system of record Expansion and innovation have produced a scaled, recurring-revenue business with accelerated growth potential AI, models and the convergence of digital and experimental workflows are transforming how science is done 43
The New Era of Scientific Discovery Where AI-driven design meets biological evidence ©2026 Revvity, Inc. Craig Monell, PhD Senior VP, Reagents David Gosalvez, PhD Chief Strategy Officer, Signals Software
©2026 Revvity, Inc. i , I . 45 Key Messages AI is driving the next era of scientific discovery DISCOVERY IS ACCELERATING More high-quality biological data will enable increased exploration, better prediction and faster prioritization BIOLOGY STILL DECIDES Experimental evidence determines what works and creates new data for continuous learning REVVITY CONNECTS BIOLOGY AND DATA Reagents, instruments and software support prediction, validation and learning
©2026 Revvity, Inc. i , I . 46 Drug discovery is entering a new era as AI expands both the scale and value of scientific data As AI expands discovery, high-quality biological data becomes increasingly important for validating hypotheses, generating new insights, and guiding scientific decisions ▪ Explore broader chemical and biological spaces ▪ Analyze complex data faster ▪ Prioritize more promising hypotheses ▪ Reveal how biological systems respond and test predictions in the lab ▪ Generate evidence that informs future discovery and strengthens computational models AI expands what can be explored, predicted and prioritized Progress increasingly depends on high-quality biological data
©2026 Revvity, Inc. i , I . 47 Historically, discovery was constrained by how much scientists could explore Previous Bottleneck Test Measure ValidateGenerate Predict Prioritize Physical Biology Screen, reveal, test and validate biology The challenge was identifying the most promising opportunities from a vast set of possibilities In-Silico Discovery Limited ability to predict at scale
©2026 Revvity, Inc. i , I . 48 AI is accelerating how scientists analyze and learn from scientific data Faster analysis and learning increase demand for decision-grade biological evidence, shifting the constraint toward evidence generation Larger, more complex datasets can be analyzed faster, shortening the cycle from experiment to insight and informing the next question MORE DATA ANALYZED BETTER INSIGHTS FROM DATA FASTER ITERATION Process larger, higher-dimensional datasets Unlock insights from previously unusable data Move more quickly to the next experiment
©2026 Revvity, Inc. i , I . 49 As discovery accelerates, the need for richer biological evidence increases In-Silico (“Virtual Lab”) Explore more, faster Physical Biology (“Wet Lab”) Reveal, test and validate biology Emerging Bottleneck Test Measure ValidateGenerate Predict Prioritize As more promising hypotheses reach the lab, richer biological validation becomes increasingly important Computation expands and accelerates discovery Biology validates and advances discovery
©2026 Revvity, Inc. i , I . Promising candidates require robust biological validation before they advance HOW DOES IT WORK? Understand cellular response DOES IT WORK? Validate biological function WHAT ELSE DOES IT AFFECT? Assess selectivity and safety No single readout tells the whole biological story 50
©2026 Revvity, Inc. i , I . 51 The next generation of computational discovery depends on high-quality experimental data… …requiring more from wet lab experimentation to inform what comes next RICHER DATA BETTER MODELS Updated with new, high-quality experimental evidence USABLE DATA BETTER PREDICTIONS Informed by larger, more complex biological datasets FASTER EXPERIMENTATION FASTER ITERATION Move more quickly to the next hypothesis
©2026 Revvity, Inc. i , I . 52 Revvity brings together biological expertise, innovative technologies and connected data Our portfolio helps scientists characterize biological responses from multiple angles, generating high-quality data and enabling a faster, more informed cycle of prediction, validation and learning INSTRUMENTS Generate and measure experimental evidence REAGENTS Reveal biological function and response SOFTWARE Connect data, context and scientific decisions
©2026 Revvity, Inc. i , I . 53 Our unique reagents and instruments enable faster, richer and more informative experimentation
©2026 Revvity, Inc. Revvity provides critical tools that generate the biological data powering AI-enabled science 54 Foundational enablers Data-rich differentiators Multimode plate readers Increase the speed and efficiency of experimentation Increase the information captured from each experiment Automation Run more experiments No-wash assays Simplify workflows Test more hypotheses High-dimensional flow cytometry Identify which cells respond Single-cell biology Understand targets, pathways and cell states High-content imaging Understand cellular response Software connecting the scientific workflow Connect experimental data, context and decisions Phenologic.AITM CytoScribeTMSelect offerings:
©2026 Revvity, Inc. Validating more promising candidates 55 Multimode plate readers and no-wash assays streamline routine screening and help scientists test more possibilities with greater speed and efficiency Foundational enablers High-performance assay technologies HTRF / AlphaLISA Scalable detection EnVision & VICTOR families More candidates are being prioritized Biological validation remains essential Simplified screening workflows No-wash assay formats reduce steps and improve throughput Miniatured high- throughput screening 1,536-well scalability increases validation throughput Broad assay coverage Specialty assays and kits span a broad set of pathways and targets
©2026 Revvity, Inc. Understanding how cells respond 56 High-content screening captures rich visual information to show how individual cells change and respond across many conditions Data-rich differentiators Capture more biological detail High-parameter reagents reveal more features in each experiment Measure complex responses at scale High-content imaging generates rich, information- dense cellular data Turn images into usable insight AI-enabled analysis helps extract meaningful patterns from complex images Customers were already generating rich biological data AI is unlocking new ways to analyze and use it More biology captured PhenoVue reagents More data generated Opera Phenix OptIQTM More information extracted Phenologic.AITM Traditional output With Phenologic.AI
©2026 Revvity, Inc. Understanding responses of cell populations 57 High-dimensional flow cytometry helps scientists see which cell populations respond and how strongly they respond in both cellular models and living subjects Data-rich differentiators Detect subtle cell populations Brighter signals with greater clarity help resolve lower-abundance markers and responses Profile more biology at once Broader panels capture more targets, pathways and cell states Turn complexity into insight Software helps analyze high- parameter data and identify meaningful patterns More biology is being measured Greater resolution reveals more meaningful variation Brighter signals Antibody-conjugates for full spectrum Broader biological coverage TotalSeqTM & LEGENDplexTM reagents Intelligent analysis Panel design + data analysis software
©2026 Revvity, Inc. Revvity is a critical enabler of wet lab experimentation 58 Faster experimentation Richer biological data More usable evidence As discovery generates more possibilities, our solutions help scientists generate the data and evidence needed to determine what advances and inform what comes next
©2026 Revvity, Inc. i , I . … Software turns data into insight for what comes next Generating more biological data is only part of the opportunity… 59
©2026 Revvity, Inc. i , I . 60 Traditionally, fragmented software offerings supported in-silico and wet lab experimental discovery separately Generate Predict vScreen V al id at e Design M ake Test D ec id e AI IN-SILICO DESIGN CYCLE TRADITIONAL WET LAB APPROACH Limited experimental feedback Sparse and disconnected data
©2026 Revvity, Inc. i , I . 61 AI is making the in-silico design cycle dramatically more powerful… Generate Predict vScreen V al id at e …But a faster design loop is only as valuable as the experimental evidence and context it can connect back to GENERATE AT GREATER SCALE Explore more molecules and hypotheses PREDICT WITH GREATER PRECISION Assess more properties before the lab PRIORITIZE WITH GREATER CONFIDENCE Advance a greater number of better candidates into testingAI-powered design
©2026 Revvity, Inc. i , I . 62 Scientists need a way to connect models and experimental evidence… …into one continuous learning system IN-SILICO Generate and prioritize hypotheses PHYSICAL BIOLOGY Test and generate experimental evidence TM
©2026 Revvity, Inc. Revvity Signals software is driving the convergence of AI design and biological validation 63 One connected environment to plan experiments, capture scientific work, connect experimental data and inform the next decision The customer’s scientific process from idea to decision Idea Next candidate The connected scientific context in a unified solution Experiments & protocols Samples, results & conditions Teams & workflows Analytics & AI Institutional memory TM TM
©2026 Revvity, Inc. Our software connects data, context and scientific insights Signals transforms experimental evidence into actionable insights AI is amplifying the value of high-quality biological data More powerful models increasingly depend on rich experimental evidence Our instruments and reagents generate critical biological evidence Enabling information-rich experiments across complex biology Revvity is positioned at the critical intersection between biological evidence and AI-driven discovery 64 Powering scientific intelligence
Driving Operational Success and Creating Long-Term Value Max Krakowiak Senior VP, CFO ©2026 Revvity, Inc.
©2026 Revvity, Inc. Key Messages 66 DIFFERENTIATED FINANCIAL PERFORMANCE Ability to deliver strong results across varying market environments OPERATIONAL EXCELLENCE Driving margin expansion, earnings growth and free cash flow ATTRACTIVE LONG-TERM POTENTIAL Durable growth powered by innovation and expanding end-market opportunities Building a track record of disciplined execution to drive long-term growth
©2026 Revvity, Inc. We have navigated a dynamic environment… 67 Post-COVID normalization 3 successive waves of market disruptions Pharma / Biotech market pressure Geopolitical and policy uncertainty 2023 2024 2025
©2026 Revvity, Inc. …Yet, since 2022, we delivered strong and above- market financial performance 68 Adj. Revenue $2B Capital deployed 0.6x Net leverage decrease 12% Reduction in share count Key Highlights Since 2022 Adj. EPS Adj. Operating Margin ~28.8% Free Cash Flow >90% FCF conversion>$575M 2026E ~$2.9B ~$5.43 2022 2026E 2022 2026E 2022 2026E
©2026 Revvity, Inc. Driving execution through the Revvity Operating Model 69 Strategic Priorities Efficiency Capturing AI-enabled productivity gains1 Simplification Creating a nimbler organization 2 Optimization Streamlining our operations3 Talent < Digitalization Agility Accountability Our Operating Model
©2026 Revvity, Inc. Efficiency: Capturing AI-enabled productivity gains 70 In the past Software engineering capacity was a key bottleneck in product development Today at Revvity Limited engineering bandwidth Longer development cycle Slower time to market Unlocking speed and impact through AI-enabled software engineering AI-enabled productivity Software engineering became an initial AI use case: 2-3x increase in productivity per developer >90% of coding projects leverage AI
©2026 Revvity, Inc. 71 Simplification: Creating a nimbler organization From 2023 to 2026 ~16% reduction in headcount Delayering of management structure to drive efficiency Advancing integration initiatives to capture synergies Driving commercial and operational synergies across LS and Dx
©2026 Revvity, Inc. 72 Optimization: Streamlining our operations ~25% Global square footage reduction Optimize the network Consolidating packaging and shipping lanes to drive logistics improvements Reduce structural cost Insourcing, product re-engineering and vendor consolidation to lower inventory and costs Increase flexibility Simplifying the footprint to improve responsiveness and resiliency From 2023 to 2026
©2026 Revvity, Inc. Executing our Revvity Operating Model… 73 …to drive long-term value creation TalentDigitalizationAgilityAccountability
©2026 Revvity, Inc. i , I . Our Attractive Long-Term Potential
©2026 Revvity, Inc. Delivered differentiated performance across dynamic market environments… 75 CAGR since becoming Revvity Life Sciences Solutions -LSD Immunodiagnostics +HSD Reproductive Health +MSD Signals Software +LDD ~20% ~25% ~10% ~45% ~$2.9B Revenue (2026E) Total Dx: +MSD Total LS: Flat Total Revvity: +LSD …and expect differentiation to continue as markets normalize Signals CAGR based on APV
©2026 Revvity, Inc. 76 Diagnostics: Strong innovation and competitive advantages driving durable growth across specialty areas
©2026 Revvity, Inc. Underlying market growth 500bps 200bps 100bps Geographic penetration Immunodiagnostics is scaling through innovation and geographic reach 77 Growth drivers 7-9% LRP organic growthInnovation Specialty diagnostics solutions with increasing automation and more actionable insights Strong innovation, increasing market adoption and expanding geographic reach Key messages
©2026 Revvity, Inc. 78 Deeper menu and geographic expansion to support future growth Above-market growth enabled by an unparalleled newborn screening solutions portfolio Key messages Reproductive Health Reproductive Health growth is driven by menu expansion and adoption Growth drivers 3-5% LRP organic growthBirth rate (headwind) -200bps 50bps Geographic expansion 200bps New products Newborn 4-6% Growth 50bps Stability in prenatal and cord blood 1-2% Growth 300bps Menu adoption
©2026 Revvity, Inc. 79 5-7% LRP organic growth Long-term outlook 7-9% 3-5% Long-term outlook ~55% of Dx ~45% of Dx Diagnostics Segment: Innovation and execution providing strong growth in specialized markets Immunodiagnostics Reproductive Health Delivering novel innovations in new markets by leveraging capabilities from across the organization Differentiated specialty diagnostics portfolio with durable competitive advantages in attractive markets Key messages
©2026 Revvity, Inc. 80 Life Sciences: Advancing discovery through connected workflows with data-rich instruments, specialized reagents and innovative software i , I .
©2026 Revvity, Inc. Life Sciences Solutions above-market growth driven by strong positioning and innovation Underlying market growth 500bps 100bps 100bps Downstream expansion 81 Growth drivers 6-8% LRP organic growth Innovation Data-rich solutions that support the discovery and validation of fundamental and complex biological insights Leveraging core capabilities to capture adjacent market opportunities Key messages
©2026 Revvity, Inc. 82 Signals is poised to grow through customer-centric innovations and solutions Expansion with existing customers 500bps 300bps 300bps New customer wins Growth drivers 10-12% APV LRP New offerings Robust innovation, scaled and entrenched platform driving sustainable long-term growth in new and existing markets Digital system of record connecting scientific workflows from idea to creation Key messages
©2026 Revvity, Inc. 83 7-9% LRP organic growth Long-term outlook 6-8% 10-12% Long-term outlook Life Sciences Solutions Signals ~85% of LS ~15% of LS Innovative specialty scientific solutions with above-market growth and attractive margins Key messages Life Sciences Segment: Delivering novel biological insights through software, reagents and instruments Integrated offerings help customers generate richer data, accelerate decisions and improve research outcomes
©2026 Revvity, Inc. LRP Organic Growth Confident in our ability to deliver above-market growth over the long term 84 Life Sciences Solutions 6-8% Immunodiagnostics 7-9% Reproductive Health 3-5% Signals Software 10-12% ~20% ~25% ~10% ~45% ~$2.9B Revenue (2026E) Total Dx: 5-7% Total LS: 7-9% 6-8% 200bps above underlying market growth Signals LRP based on APV
©2026 Revvity, Inc. 85 Achieving top- tier margins with industry-leading potential ~28.8% Adj. Operating Margin (%) 2026E Gross margin expansion FutureSG&A operating leverage and cost efficiencies 25bps per year 50bps per year Mid 30s% Incremental adj. op. margins in the low 40s%
©2026 Revvity, Inc. 86 Strong and differentiated long-term financial outlook 75bps operating margin expansion 3% Organic revenue growth (200bps above market) 6-8% Double Digits Adj. EPS growth With several areas for potential upside
©2026 Revvity, Inc. Complemented by disciplined capital deployment 87*Future capital allocation will vary to target highest-return opportunities Buybacks Dividends M&A Historical (2023-2026E) Future Intentions* (2027-2031) Targeted M&A to complement capabilities across Life Sciences Consistent share repurchases Maintain existing dividend ~$5B of capital capacity through 2031 with commitment to investment-grade credit rating
©2026 Revvity, Inc. Areas of potential upside beyond the LRP Outsized AI-driven demand Additional strategic partnerships Disciplined and opportunistic capital deployment 88
©2026 Revvity, Inc. ~6% organic growth ~200bps above market growth ~20bps in addition to normal operating leverage Net Interest = ~$85M Tax Rate = ~19% Share Count = Flat Formal 2027 guidance to be provided on our Q4 earnings call Organic Growth Margin Expansion Below the Line 2027 considerations 89
©2026 Revvity, Inc. Key messages from today 90 Powering Scientific Intelligence by bringing together biological expertise, innovative technologies and connected data Revvity is: Revolutionizing science and transforming human lives through groundbreaking innovation Delivering compelling long-term value creation through our differentiated portfolio
©2026 Revvity, Inc. i , I .